Dr. Copeland will present on mechanism-driven approaches to molecularly targeted cancer drug discovery.
Oncology drug discovery at GlaxoSmithKline is focused on molecularly targeted therapeutics for the treatment of cancer and for cancer supportive care indications. A guiding principle of the company’s approach is that a detailed, mechanistic understanding of pathobiology and of drug action – at the molecular, cellular and organismal level – is essential for effective drug discovery. Towards this end GlaxoSmithKline has built a discovery organization that encompasses robust biochemical, cellular biological and in vivo pharmacological interrogation of drug candidates. Examples of the application of these approaches to several cancer drug-seeking efforts will be presented at the conference.
Jeffrey Hanke, Vice President of Cancer Research at AstraZeneca, will also give a keynote presentation.
Dr. Hanke will present on developing new therapeutics for the treatment of cancer. He will discuss challenges and opportunities within the field of cancer drugs.
AstraZeneca’
The 5th Cancer Drugs Research & Development conference features presentations on the successes and setbacks of modern cancer drugs, new drug compounds and future drugs for the treatment and prevention of cancer, cancer drug development in clinical trials and new drug delivery methods. For more information, visit www.gtcbio.com.
